A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Conditions
- Human Immunodeficiency Virus Infections
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 58
- Registration Number
- NCT03563742
- Locations
- 🇮🇳
Chennai Antiviral Research and Treatment(CART) Clinical Research Site, Chennai, India
🇮🇳YRGCARE, Chennai, India
🇮🇳Manipal University-Kasturba Medical College, Mangalore, India
A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 181
- Registration Number
- NCT03559192
- Locations
- 🇺🇸
Noble Clinical Research, Tucson, Arizona, United States
🇷🇺Psychoneurological dispensary 1, St-Petersburg, Russian Federation
🇺🇦Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3', Kharkiv, Ukraine
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ-64232025 SCDrug: JNJ-64232025 IVDrug: Placebo
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT03550950
- Locations
- 🇧🇪
SGS Life Science Services, Antwerpen, Belgium
A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Castration-Resistant Prostatic Neoplasms
- Interventions
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT03551782
- Locations
- 🇨🇦
University of Toronto, Toronto, Ontario, Canada
🇺🇸Regional Urology LLC, Shreveport, Louisiana, United States
🇺🇸University of California San Francisco (UCSF) - Prostate Cancer Center, San Francisco, California, United States
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Biological: JNJ-68284528
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 126
- Registration Number
- NCT03548207
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇯🇵University Hospital Kyoto Perfectural University of Medicine, Kyoto, Japan
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT03546205
- Locations
- 🇺🇸
AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville, Tennessee, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Fluoroquinolone Associated Disability
- Conditions
- Urinary Tract InfectionsBronchitisSinusitis
- Interventions
- Drug: Fluoroquinolone (FQ)Drug: Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 239306
- Registration Number
- NCT03535558
- Locations
- 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States
A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 19
- Registration Number
- NCT03523442
- Locations
- 🇨🇳
Beijing Cancer Hospital of Peking University, Beijing, China
🇨🇳Jiangsu Cancer Hospital, NanJing, China
🇨🇳Peking University Third Hospital, Beijing, China
A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 516
- Registration Number
- NCT03517722
- Locations
- 🇺🇦
Odeska oblasna klinichna likarnia, Odesa, Ukraine
🇺🇦Multidisciplinary Medical Center of Odessa National Medical University, Odessa, Ukraine
🇷🇺Clinical Diagnostic Center 'Ultramed', Omsk, Russian Federation
A Study of Bermekimab in Patients With Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- First Posted Date
- 2018-04-30
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 42
- Registration Number
- NCT03512275
- Locations
- 🇺🇸
Tennessee Clinical Research Center, Nashville, Tennessee, United States